





Safety notices and Vigilance

Opportunities and challenges – Industry perspective

Miang Tanakasemsub Regional Regulatory Affairs Head, Johnson & Johnson Vision Asia Pacific GHWP TC Vice Chair APACMED RA committee Chair

27 March 2023

OVERVIEW

- Postmarket Surveillance/ Vigilance
- Summary PMS activities & Links to International Standards
- Regional/Markets Key challenges
- Key Opportunities



Postmarket surveillance/ Vigilance

Vigilance

Post Market Surveillance



Vigilance: <u>reacting</u> to adverse event

Post Market surveillance: proactive collection of information





The reporting and investigation of adverse events. Both the manufacturer and the Regulatory Authority play major roles.



Post market surveillance:


Post market collection of info on the quality, safety and performance of a MD by Regulatory Authorities or Manufacturers.

→ Injury prevention, Product improvement, Regulatory measures,





Summary PMS activities & Links to International Standards (*)





(*) Reference: section 9.2 of GHWG-GRM/N1R13 (2011)

Regional/Markets Key challenges

- Different Definitions
 - Adverse Events
 - FSCA
- Different AE reporting criteria
- Foreign AE report requirements
- No common AE/FSCA reporting forms
- Different reporting timelines
- Different Annual/PSUR reports requirements
- Multiple UDIs systems



Example SAE Reporting Timelines

China

 Not later than 7 days for events that led to death or serious deterioration in state

of health,

- Not later than 20 days for events that led to serious injury that happen in China.
- Not later than 30 days for events that led to serious injury that happen overseas

Japan

- Unlabeled serious incidents or near incidents 15 days
- Labeled serious incidents or near incidents – 30 days
- Unlabeled medium level incidents or near incidence – 30 days
- Serious incidents by infectious diseases that could be caused by using medical devices – 15 days.

Australia

 Death or serious deterioration in health: 10 days

Hong Kong SAR

 Deaths, serious injuries, or events of serious public health concern: 10 elapsed calendar days

Singapore

 Not later than 10 days for events that led to death or serious deterioration in state of health,



Example Not reportable Criteria

China

 There are no definite provisions for "Not Reportable Events"

Australia

- Events occurred outside Australia.
- by the user prior to its use
- Adverse incident caused solely by patient conditions
- Use of a medical device beyond its service life
- Protection against a fault functioned correctly
- Remove likelihood of occurrence of death or serious injury
- Expected and foreseeable side effects that are documented in manufacturer's instructions for use or labelling
- Adverse events described in an advisory notice
- Reporting exemptions granted by the Therapeutic Goods Administration

Hong Kong SAR

- Incidents occurred outside of Hong Kong
- Deficiency of a new device found by the user prior to its use
- Adverse incident caused by patient conditions
- Use of a medical device beyond its service life
- Protection against a fault functioned correctly and where no death or serious injury occurs
- Remote likelihood of occurrence of death or serious injury
- Expected and foreseeable side effects
- Adverse incidents described in an advisory notice previously sent to users
- Use errors
- Adverse incidents cause by abnormal use

Singapore

• Events occurred outside Singapore.

Japan

 There are no definite provisions for "Not Reportable Events" except for mishandling or user error.

Key Opportunities

- Harmonization definition/criteria/timelines/reporting forms
- Consider annual safety report requirements over foreign AE reporting requirements
- Consider Post Market requirements to be part of Renewal/ Recertification/ New medical device regulation requirements





THANK YOU / QUESTIONS

ctanakas@its.jnj.com

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.





